Shares of Valeant Pharmaceuticals plunged in premarket trading, amid ongoing turmoil over the embattled drugmaker's delayed financial results and its leader's health.
Even news Sunday that CEO Michael Pearson is returning after nine weeks recovering from pneumonia couldn't buoy Valeant shares.
They fell 6.1 percent to $75.74 in premarket trading Monday about an hour before the market open.
Investors, relieved over the end of the mystery about Pearson's status, are again focusing on Valeant's delayed financial results and future expectations.
Valeant was to have publicly released preliminary fourth-quarter and 2015 results and discussed 2016 prospects om Monday. Now it says it will do so "in the near term." It also has withdrawn all its financial forecasts.
Last week, Valeant said it wouldn't file results with regulators until in resolves questions about how some revenue was recorded.